Non‐Hodgkin lymphoma of the prostate
暂无分享,去创建一个
D. Weisenburger | P. Bierman | J. Vose | M. Bast | H. Kantarjian | G. Garcia-Manero | C. Meyers | S. Faderl | F. Loberiza | S. Pierce | R. Bociek | Susan M. Wood | James O. Armitage | John Steuter
[1] P. Treseler,et al. Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] L. Rybicki,et al. Vitamin D level after allogeneic hematopoietic stem cell transplant. , 2011, Biology of Blood and Marrow Transplantation.
[3] V. Nosikov,et al. The carriage of the type 1 diabetes‐associated R262W variant of human LNK correlates with increased proliferation of peripheral blood monocytes in diabetic patients , 2011, Pediatric diabetes.
[4] R. Chopra,et al. A review of the history, properties, and use of the immunomodulatory compound lenalidomide , 2011, Annals of the New York Academy of Sciences.
[5] D. Amadori,et al. Prolonged 18FDG‐PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor (Rd‐G) , 2011, American journal of hematology.
[6] S. Chevret,et al. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms. , 2010, Blood.
[7] Hanlee P. Ji,et al. Identification of Novel LNK Mutations In Patients with Chronic Myeloproliferative Neoplasms and Related Disorders , 2010 .
[8] P. Guglielmelli,et al. LNK Mutation Studies In Chronic- and Blast-Phase Myeloproliferative Neoplasms and JAK2 Mutation-Negative Erythrocytosis , 2010 .
[9] A. Tefferi,et al. LNK mutations in JAK2 mutation-negative erythrocytosis. , 2010, The New England journal of medicine.
[10] A. Tefferi,et al. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations , 2010, Leukemia.
[11] Erin F. Simonds,et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. , 2010, Blood.
[12] C. van Weel,et al. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. , 2010, Archives of internal medicine.
[13] Mondira Kundu,et al. Lnk constrains myeloproliferative diseases in mice. , 2010, The Journal of clinical investigation.
[14] K. Ataga,et al. The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐up , 2010, American journal of hematology.
[15] A. Vincent-Salomon,et al. Primary high‐grade ocular adnexal lymphoma: Clinicopathological characteristics and prognostic factors of a single‐centre series , 2010, American journal of hematology.
[16] E. Terpos,et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). , 2010, Blood.
[17] M. McMullin. HIF pathway mutations and erythrocytosis , 2010, Expert review of hematology.
[18] C. Thornburg,et al. Adherence to study medication and visits: Data from the BABY HUG trial , 2009, Pediatric blood & cancer.
[19] B. Barton,et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. , 2009, Journal of the National Medical Association.
[20] Michael L. Wang,et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo , 2009, American journal of hematology.
[21] M. Chonchol,et al. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. , 2009, Atherosclerosis.
[22] Andrew D. Johnson,et al. Genome-wide association study of blood pressure and hypertension , 2009, Nature Genetics.
[23] P. O’Reilly,et al. Genome-wide association study identifies eight loci associated with blood pressure , 2009, Nature Genetics.
[24] S. Gery,et al. Lnk inhibits myeloproliferative disorder‐associated JAK2 mutant, JAK2V617F , 2009, Journal of leukocyte biology.
[25] A. Ferreri,et al. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options , 2009, Hematological oncology.
[26] I. Lossos,et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma , 2009, British journal of haematology.
[27] A. Osunkoya,et al. Lymphoid neoplasms of the urinary tract and male genital organs: a clinicopathological study of 40 cases , 2009, Modern Pathology.
[28] D. Postma,et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction , 2009, Nature Genetics.
[29] Cisca Wijmenga,et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. , 2008, The New England journal of medicine.
[30] Chao Wu,et al. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. , 2008, The Journal of clinical investigation.
[31] C. Haywood,et al. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network. , 2008, Journal of the National Medical Association.
[32] L. Adorini,et al. Control of autoimmune diseases by the vitamin D endocrine system , 2008, Nature Clinical Practice Rheumatology.
[33] B. Pollock,et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. , 2008, Annals of internal medicine.
[34] Renee F Wilson,et al. Systematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell Disease , 2008, Annals of Internal Medicine.
[35] E. Rimm,et al. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. , 2008, Archives of internal medicine.
[36] David S Sanders,et al. Newly identified genetic risk variants for celiac disease related to the immune response , 2008, Nature Genetics.
[37] A. Gopal,et al. Radioimmunotherapy-based conditioning regimens for stem cell transplantation. , 2008, Seminars in hematology.
[38] Phyllis C Everett. The prevalence of vitamin D deficiency and insufficiency in a hematology-oncology clinic. , 2008, Clinical journal of oncology nursing.
[39] P. McCarthy,et al. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy , 2008, Bone Marrow Transplantation.
[40] A. Colao,et al. REVIEW: Bone Loss and Its Management in Long-Term Survivors from Allogeneic Stem Cell Transplantation , 2007 .
[41] P. Ames,et al. Consecutive pseudogout attacks after repetitive granulocyte colony-stimulating factor administration for neutropenia , 2007, Modern rheumatology.
[42] E. Thiel,et al. Diagnosis and management of primary intraocular lymphoma: an update , 2007, Clinical ophthalmology.
[43] P. Hinds,et al. Therapy preference and decision‐making among patients with severe sickle cell anemia and their families & , 2007, Pediatric blood & cancer.
[44] A. Barrett,et al. Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[45] M. Percy,et al. Genetically heterogeneous origins of idiopathic erythrocytosis , 2007, Hematology.
[46] E. Hyppönen,et al. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. , 2007, The American journal of clinical nutrition.
[47] C. Haywood,et al. Hospitalization rates and costs of care of patients with sickle‐cell anemia in the state of Maryland in the era of hydroxyurea , 2006, American journal of hematology.
[48] M. Gulliford,et al. Measuring Continuity of Care in Diabetes Mellitus: An Experience-Based Measure , 2006, The Annals of Family Medicine.
[49] R. Vieth. What is the optimal vitamin D status for health? , 2006, Progress in biophysics and molecular biology.
[50] S. Akira,et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. , 2006, The Journal of clinical investigation.
[51] Yan Liu,et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. , 2006, Journal of the National Cancer Institute.
[52] M. Lampl,et al. Parents' Assessment of Risk in Sickle Cell Disease Treatment With Hydroxyurea , 2005, Journal of pediatric hematology/oncology.
[53] J. Scott,et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. , 2005, Blood.
[54] M. Albitar,et al. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome , 2005, Cancer.
[55] P. Campbell,et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis , 2005, British journal of haematology.
[56] H. Lodish,et al. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. , 2005, Blood.
[57] T. Konrad,et al. Hydroxyurea therapy for sickle cell disease in community‐based practices: A survey of Florida and North Carolina hematologists/oncologists , 2005, American journal of hematology.
[58] M. Holick,et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. , 2005, The Journal of clinical endocrinology and metabolism.
[59] Diana De. Sickle cell anaemia 2: management approaches of painful episodes. , 2005, British journal of nursing.
[60] S. Ballas,et al. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance , 2005, American journal of hematology.
[61] P. Chu,et al. Incidental and Concurrent Malignant Lymphomas Discovered at the Time of Prostatectomy and Prostate Biopsy: A Study of 29 Cases , 2005, The American journal of surgical pathology.
[62] Béatrice Gulbis,et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. , 2005, Blood.
[63] P. Lips,et al. Estimates of optimal vitamin D status , 2005, Osteoporosis International.
[64] J. Finke,et al. Treatment with granulocyte colony‐stimulating factor increases interleukin‐1 receptor antagonist levels during engraftment following allogeneic stem‐cell transplantation , 2004, European journal of clinical investigation.
[65] Harvey F. Lodish,et al. Lnk Inhibits Tpo–mpl Signaling and Tpo-mediated Megakaryocytopoiesis , 2004, The Journal of experimental medicine.
[66] P. Jacobsen,et al. Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. , 2004, Journal of pain and symptom management.
[67] S. Emans,et al. Prevalence of vitamin D deficiency among healthy adolescents. , 2004, Archives of pediatrics & adolescent medicine.
[68] C. Schulte,et al. Bone loss following hematopoietic stem cell transplantation: a long-term follow-up. , 2004, Blood.
[69] R. Ware,et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. , 2004, Blood.
[70] S. Davies,et al. The role of hydroxyurea in the management of sickle cell disease. , 2003, Blood reviews.
[71] W. Au,et al. Unusual sites of involvement in non-Hodgkin's lymphoma: Case 1. Isolated orbit relapse after allogeneic bone marrow transplantation for malignant lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] K. Schulz,et al. Bias and causal associations in observational research , 2002, The Lancet.
[73] O. Rosen,et al. Loss of bone mass and vitamin D deficiency after hematopoietic stem cell transplantation: standard prophylactic measures fail to prevent osteoporosis , 2001, Leukemia.
[74] E. Vermeire,et al. Patient adherence to treatment: three decades of research. A comprehensive review , 2001, Journal of clinical pharmacy and therapeutics.
[75] I. Day,et al. An efficient procedure for genotyping single nucleotide polymorphisms. , 2001, Nucleic acids research.
[76] C. Thauvin-Robinet,et al. Exposure to hydroxyurea during pregnancy: a case series , 2001, Leukemia.
[77] I. Hambleton,et al. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study , 2001, The Lancet.
[78] O. Platt,et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. , 1999, Blood.
[79] Y. Ouchi,et al. [An elderly case with pseudogout exacerbated by the administration of granulocyte-colony stimulating factor during drug-induced granulocytopenia]. , 1999, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.
[80] T. Spitzer,et al. Acute gouty arthritis following recombinant human granulocyte colony-stimulating factor therapy in an allogeneic blood stem cell donor. , 1998 .
[81] Ralph H. B. Benedict,et al. Hopkins Verbal Learning Test—Revised: Normative data and analysis of inter-form and test–retest reliability. , 1998 .
[82] D. Cella,et al. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. , 1997, Seminars in hematology.
[83] H. Müller-Hermelink,et al. Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. , 1997, Blood.
[84] M. Buyse,et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. , 1996, Blood.
[85] R. Parks,et al. Primary non-Hodgkin's lymphoma of the prostate mimicking acute prostatitis. , 1995, British journal of urology.
[86] D G Altman,et al. Statistics notes: Absence of evidence is not evidence of absence , 1995 .
[87] A. Sarris,et al. Primary lymphoma of the prostate: good outcome with doxorubicin-based combination chemotherapy. , 1995, The Journal of urology.
[88] M L Terrin,et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. , 1995, The New England journal of medicine.
[89] O. Platt,et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.
[90] S. Culine,et al. [Primary, highly malignant B-cell lymphoma of the prostate. Apropos of a case and review of the literature]. , 1994, Bulletin du cancer.
[91] M. Okada,et al. [Primary non-Hodgkin lymphoma of the prostate: a case report]. , 1993, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.
[92] W. Petros,et al. Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support. , 1993, Blood.
[93] S. Segalowitz,et al. CNV evidence for the distinctiveness of frontal and posterior neural processes in a traumatic brain-injured population. , 1992, Journal of clinical and experimental neuropsychology.
[94] J. T. Marsh,et al. Cognitive function, mood and P3 latency: Effects of the amelioration of anemia in dialysis patients , 1991, Neuropsychologia.
[95] K. Kerbl,et al. Primary non-Hodgkin lymphoma of prostate. , 1988, Urology.
[96] E. Henderson,et al. Primary prostatic involvement in non-Hodgkin lymphoma. , 1988, Urology.
[97] S. Pocock,et al. Statistical problems in the reporting of clinical trials. A survey of three medical journals. , 1987, The New England journal of medicine.
[98] Joshua R. Smith,et al. Primary lymphoma of prostate presenting as bladder outflow obstruction. , 1987, Urology.
[99] D. Bostwick,et al. Malignant lymphomas involving the prostate a study of 13 cases , 1985, Cancer.
[100] T. Oppé,et al. Vitamin D deficiency. , 1979, British medical journal.
[101] D. Mccarty,et al. Preliminary criteria for the classification of the acute arthritis of primary gout. , 1977, Arthritis and rheumatism.
[102] D. Mulrooney,et al. Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients , 2011, Bone Marrow Transplantation.
[103] A. Colao,et al. Bone loss and its management in long-term survivors from allogeneic stem cell transplantation. , 2007, The Journal of clinical endocrinology and metabolism.
[104] C. Elie,et al. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. , 2006, Haematologica.
[105] Matthew W. Darlison,et al. The role of the haemoglobinopathy nurse counsellor: an exploratory study. , 2000, Journal of advanced nursing.
[106] R. Cabeza,et al. Imaging Cognition II: An Empirical Review of 275 PET and fMRI Studies , 2000, Journal of Cognitive Neuroscience.
[107] T. Priestman,et al. Lymphoma of the prostate treated with radiotherapy. , 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).
[108] R. Morgan,et al. Primary non-Hodgkin's lymphoma of the prostate gland: case report and review of the literature. , 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).
[109] J. Peters,et al. Primary prostatic lymphoma: a rare prostatic malignancy. , 1994, The Australian and New Zealand journal of surgery.
[110] R. A. Knight,et al. Primary non-Hodgkin lymphoma of the prostate gland. , 1993, International urology and nephrology.
[111] R. Hast,et al. Therapeutic aspects of myelodysplastic syndromes in chronic phase. , 1992, Leukemia research.